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Understanding the role of neuropilin 2 (NRP2) in prostate cancer cells as well as in the bone microenvironment is pivotal in the
development of an effective targeted therapy for the treatment of prostate cancer bone metastasis. We observed a signiﬁcant
upregulation of NRP2 in prostate cancer cells metastasized to bone. Here, we report that targeting NRP2 in cancer cells can enhance
taxane-based chemotherapy with a better therapeutic outcome in bone metastasis, implicating NRP2 as a promising therapeutic
target. Since, osteoclasts present in the tumor microenvironment express NRP2, we have investigated the potential effect of
targeting NRP2 in osteoclasts. Our results revealed NRP2 negatively regulates osteoclast differentiation and function in the
presence of prostate cancer cells that promotes mixed bone lesions. Our study further delineated the molecular mechanisms by
which NRP2 regulates osteoclast function. Interestingly, depletion of NRP2 in osteoclasts in vivo showed a decrease in the overall
prostate tumor burden in the bone. These results therefore indicate that targeting NRP2 in prostate cancer cells as well as in the
osteoclastic compartment can be beneﬁcial in the treatment of prostate cancer bone metastasis.
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INTRODUCTION
Bone is the most common metastatic site for castration-resistant
prostate cancer.1 Nearly 70%–80% of the patients with advancedstage prostate cancer (PCa) develop skeletal metastases which
remains as the most common cause of deaths in these patients.
The 1-year survival rate in patients with metastatic PCa without
incidence in bone is at nearly 87%, which is reduced to 47% in
patients with bone metastasis.2 Only 3% of patients with bone
metastasis survive after 5 years compared to 56% patients without
bone metastasis.3 In addition, PCa patients with bone metastasis
frequently suffer from skeletal-related events (SREs) such as severe
bone pain, pathologic fractures, spinal cord and nerve compression
syndromes, and hypercalcemia.4,5 Current treatment strategy for PCa
patients with metastatic bone disease includes taxane-based
chemotherapy, which can effectively limit the progression of the
disease for a short time period but patients eventually relapse within
the ﬁrst year of treatment.6–9 To date, bone metastasis remains as a
frequent and fatal complication in PCa patients, and its management
is a clinical challenge. Thus, new molecular target(s) that can be
therapeutically exploited are needed to improve patient outcomes. A
major consideration in this effort is that treatment strategies for PCa
cells metastasized to bone are also likely to inﬂuence the normal bone
cells present at the site of metastatic lesions. This is because the
metastatic disease results from an interplay between cancer cells and
the bone cells namely osteoblasts and osteoclasts, which contributes

to a vicious cycle that provides a fertile soil for metastatic growth of
cancer cells in the bone.1,10,11 Radiographic studies of PCa patients
with bone involvement characterized bone metastases as osteoblastic
lesions as opposed to osteolytic lesions with decreased bone mineral
density.12 In fact, PCa bone metastases show a heterogeneous blend
of osteoblastic and osteolytic functions with the balance shifted to
favor osteoblastic metastasis. Because of this multifaceted interplay
between PCa cells and bone cells, it is important to test how a
potential therapy against metastatic PCa cells can inﬂuence the
function of bone cells.
The NRPs are type-I transmembrane glycoproteins belonging to a
family of non-tyrosine kinase, cell surface receptors that function in
multiple cellular signaling pathways in normal physiology as well as
pathological conditions.13,14 They are over-expressed in various
neoplasms and correlates with stress-induced cancer survival,
progression, metastasis, and poor prognosis.15–17 We have previously observed the role of NRP2 in protecting PCa cells against
chemotherapies in vitro.18,19 In this study, we addressed how
inhibition of the functions of NRP2 affects PCa cells in PCa bone
metastasis, thus highlighting the potential of NRP2-targeted therapy
to beneﬁt PCa patients with bone metastasis. Our study also
investigated the function of NRP2 in osteoclasts present in the
bone microenvironment in promoting PCa bone metastasis, as it is
known to be expressed in these cells.20 We have elucidated a
novel function of NRP2 as a negative regulator of osteoclast
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differentiation and function in PCa bone metastasis. Interestingly,
our ﬁndings imply that PCa-induced NRP2 expression in
osteoclasts is necessary for low osteolytic activity in PCa bone
metastasis with mixed lesions and that PCa, which is predominantly osteolytic in nature, evades NRP2 inhibition. Interestingly,
knocking out NRP2 in osteoclasts in a PCa model of bone
metastasis signiﬁcantly inhibited tumor growth. Our study thus
eludicated the overall effect of targeting NRP2 in both cancer cells
and osteoclasts in PCa bone metastasis, which can prove to be
beneﬁcial in the development of an effective treatment strategy.
RESULTS
NRP2 is a potential therapeutic target in treating PCa bone
metastasis
High expression of NRP2 in human PCa bone metastasis. To
address whether NRP2 is present in human PCa bone metastasis,
we evaluated its expression by immunohistochemistry both in
human primary PCa tissues and in PCa bone metastasis. For this, a
bone metastatic tissue microarray was purchased from TriStar
Technology (Rockville, MD, USA.) which contained samples of ﬁfty
patients. The primary PCa cohort was obtained from radical
prostatectomy specimens of 130 patients with non-metastasized
but locally advanced PCa (pT3a or pT3b/4, all pN0) treated at
Mayo Clinic between 1992 and 1997 (refer to the methods
section). On comparing the tissues, heterogeneous expression of
NRP2 was observed in primary PCa while expression of NRP2 was
higher and more homogenous in PCa bone metastasis (Fig. 1a).
Nearly 85% of the tissues from PCa bone metastasis showed high
NRP2 expression. We also observed no expression of NRP2 in the
normal prostate (Supplementary Fig. 1a). Analysis of RNA-seq
data from metastatic castration-resistant PCa (CRPC) patients
revealed that NRP2 expression in bone is signiﬁcantly higher as
compared to the other visceral and soft tissue metastatic sites
(https://www.cbioportal.org/study/summary?id=prad_su2c_2019)
(Fig. 1b).21 These results therefore indicated a potential role of
NRP-2 in bone metastatic PCa.
Targeting NRP2 in combination with chemotherapeutic agents is
effective against PCa cells in a bone metastasis model. Our
previous in vitro studies implicated NRP2 in promoting survival
of cancer cells under chemotherapeutic stress via autophagy.18,19,22 Since we observed increased expression of NRP2 in
PCa metastasized to bone, we hypothesized that targeting the
NRP2 axis in PCa bone metastasis will sensitize cancer cells to
chemotherapy. We therefore tested whether depletion of NRP2 in
the mouse model of bone metastasis would sensitize prostate
tumor to docetaxel. We have developed stable shNRP2 expressing
clones of LNCaP C4-2B (an mCRPC cell line), where shRNA can be
inducibly expressed upon administration of doxycycline. The
requirement of NRP2 for PCa growth in bone was tested by
implanting shNRP2-expressing LNCaP C4-2B cells in the tibia of
immunocompromised mice and then knocking down NRP2 from
cancer cells in combination with docetaxel (Fig. 1c). Depletion of
NRP2 in tumor cells was conﬁrmed by mRNA analysis of tumor
cells isolated from the mouse bones (Supplementary Fig. 1b). No
change was observed in the weight of the mice as well as their
ability to drink water containing either sucrose alone or
doxycycline in sucrose in all the experimental groups (Supplementary Fig. 1c, d). LNCaP C4-2B develops bone metastases that is
characterized by their loss/destruction/reformation of bone tissue
measured by bone morphometric analysis. Inhibition of bone
metastases formation is consequently indicated by an increase in
bone mass. Bone morphometric analysis showed a signiﬁcant
bone loss in the control (LNCaP C4-2B only) as well as in docetaxel
only group. By contrast, NRP2 depletion in the tumor cells reduced
bone destruction, indicating an inhibition of growth of PCa cells
in bone. The bone mass recovery was more profound in the

combination group which had NRP2 depletion in tumor cells and
received docetaxel (Fig. 1d). Evaluation of standard H&E-stained
and EDTA-decalciﬁed slides of the bone metastatic site revealed
intact tumor cells without any necrosis in the control group.
Docetaxel treatment alone clearly increased the necrotic area.
Also, the group with silenced NRP2 in the tumor cells demonstrated increased necrosis. Almost all the metastatic lesions
became necrotic when combining NRP2 depletion with taxanebased chemotherapy (Fig. 1e). To validate these results, we
measured Ki67 proliferation as well as cleaved caspase 3 as an
indicator of apoptosis in the metastatic lesions. In comparison to
the control, apoptosis was increased in the groups receiving
chemotherapy alone and NRP2 depletion alone. Metastatic lesions
treated with both NRP2 silencing and docetaxel showed the
highest proportion of apoptotic cells. In line with these results, the
fraction of proliferating tumor cells was signiﬁcantly decreased in
both the NRP2-depletion and the combination group compared
with the control (Fig. 1f–i). These data cumulatively suggest that
targeting NRP2 in PCa cells growing in bone may enhance therapy
in combination with standard chemotherapeutic agents.
Targeting the NRP2 axis affects the function of osteoclasts
differentiated by factors released by the metastatic PCa
While the above results suggested NRP2 is a potential target to
treat PCa patients with bone metastasis, the potential effect of
targeting NRP2 in non-cancer cells in the tumor microenvironment is not known. Osteoclasts express NRP2 and are reported to
be early propagators of PCa bone metastasis. Thus, we
investigated how inhibition of NRP2 might affect the function
of these cells in the context of PCa bone metastasis.
PCa cell induced NRP2 expression in osteoclasts. We used two
bone metastatic PCa cell lines: LNCaP C4-2B and PC3. Being a
derivative of LNCaP with its ability to metastasize to bone, LNCaP
C4-2B is a PCa cell line that can induce bone lesions with mixed
osteoblastic and osteolytic function.23,24 PC3 is a bone metastatic
PCa cell line, which promotes high osteolytic lesions with minimal
or no osteoblastic function.25,26 Osteoclast precursors were
isolated from the bone marrow of C57BL6 mice (forelimbs and
hind limbs) and were differentiated using RANKL and M-CSF
(control condition) and conditioned medium (CM) from PC3 and
LNCaP C4-2B cells separately. M-CSF and RANKL signaling is
central to osteoclast differentiation under physiological condition.27 The differentiation was conﬁrmed by tartarate-resistant
acid phosphatase (TRAP) staining, released TRAP levels in the
media and a pit resorption assay (Supplementary Fig. 2a–f, h). The
expression of osteoclastic genes such as RANK, TRAP, cathepsin-k,
DC-stamp, ATP6V0D2, metalloprotease 9 and carbonic anhydrase
(Supplementary Fig. 2g) was also measured as markers for
differentiation.
We tested for the expression of NRP2 and found that osteoclasts
expressed NRP2 in all three conditions. A time course study
(0–6 days) in the differentiating osteoclasts revealed that NRP2
expression increases with time both at the transcriptional and
protein levels (Fig. 2a, b).
NRP2 differentially regulates the function of osteoclasts differentiated
by osteosclerotic vs osteolytic PCa factors. To understand the
signiﬁcance of inhibiting NRP2 in osteoclasts in bone metastatic
PCa, we depleted NRP2 in osteoclast precursors and induced
osteoclastic differentiation using control and PCa CM treatment.
NRP2 was depleted/deleted either by silencing with siRNA against
NRP2 or using a transgenic mouse model, NRP2 Flox/Flox; CSF1R-cre
where NRP2 is speciﬁcally deleted in osteoclast precursors by the
addition of hydroxytamoxifen. In the RANKL and M-CSF condition,
we found extremely large multinucleated structures in NRP2depleted or -deleted osteoclasts by TRAP staining and a signiﬁcant
increase in TRAP activity (Fig. 2c, f, Supplementary Figs. 3a, 4a, 4e).
Bone Research (2021)9:24
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Fig. 1 Targeting NRP2 in prostate cancer cells in PCa bone metastasis is effective in combination with chemotherapy. a Top: Representative
immunohistochemical staining of NRP2 expression in human primary prostate cancer and prostate cancer bone metastasis. Bottom: Table
showing the percentage positivity of NRP2 staining intensity distinguished as No, intermediate and strong staining in human primary prostate
cancer and prostate cancer bone metastasis tissues. b Dot-plot graph depicting the expression of NRP2 from RNA- seq data of mCRPC patients
comparing between metastatic sites: bone vs other soft or visceral tissue sites. c Schematic diagram of the intratibial injection of LNCaP C4-2B
containing inducible NRP2 shRNA. At day 7, the mice were sorted based on the bioluminescence imaging and divided into four groups:
control, docetaxel alone, doxycycline in water and combination of doxycycline in water and docetaxel. d Representative micro-CT images of
trabecular compartment of the proximal tibia for normal bone and all four treatment groups. Graphs showing bone mass density (BMD), bone
volume/tissue volume (BV/TV) and trabecular number per mm area for each group. For each group, n = 6 mice were used to analyze tumor
bearing bones from two independent experiments. e Representative H&E images for each treatment group depicting the status of tumor cells
in the tibia of mice. f, g Immunoﬂuorescence images showing the expression of Ki67 (proliferation marker) and cleaved caspase 3 (apoptosis
marker) for each group respectively in pink along with respective area showing tumor cells in green. h, i Graphs representing the
quantiﬁcation of the mean corrected total cell ﬂuorescence for Ki67 and cleaved caspase 3 (pink) with respect to tumor cells (green). All data
are shown as mean ± standard error of mean (SEM). Statistical signiﬁcance was calculated by student t-test and P value denoted as NS (not
signiﬁcant), * (0.05), ** (0.01), *** (0.001)

We also observed a greater number of osteoclasts in the NRP2deleted condition (Fig. 3c). Similarly, depletion of NRP2 in
osteoclasts exposed to LNCaP C4-2B CM resulted in elevated
osteoclast differentiation and function compared with NRP2-intact
cells (Fig. 2d, g). These cells also fused into giant, multinucleated
structures with increased TRAP activity, even by day 4 (Fig. 2d, g,
Supplementary Figs. 3c, 4b, g).
Interestingly, in PC3 CM-induced osteoclasts, absence of NRP2 did
not affect osteolytic differentiation and activation. Further, osteoclasts
induced by PC3 CM showed no difference in TRAP staining and TRAP
activity after NRP2 reduction compared to the control (Fig. 2e, h,
Supplementary Figs. 3e, 4c, i). The number of osteoclasts attached to
Bone Research (2021)9:24

the plate increased after NRP2 deletion in PC3 CM, although the
increase did not reach signiﬁcance (Fig. 2h). We were able to
efﬁciently delete or deplete NRP2 by knockout or siRNA in all three
conditions (Supplementary Figs. 3b, d, f and 4d, f, h).
To validate the augmented osteoclast activity after NRP2
depletion, a pit resorption assay was performed. The results
demonstrated increased bone resorption in differentiated NRP2null osteoclasts in comparison to NRP2-positive osteoclasts exposed
to RANKL and M-CSF (Fig. 3a, d). On day 4 of differentiation, NRP2depleted osteoclasts started to fuse with each other and form a
polykaryon. By day 5, these multinucleated osteoclasts started
resorbing the surface of the osteoassay plate actively. We observed a
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signiﬁcant increase in the area of the resorbed pit in NRP2-deleted
osteoclasts in comparison to NRP2-expressing cells (Fig. 3a, d). By day
6, nearly 70% of the surface of the osteoassay plate was resorbed
due to deletion of NRP2. Thus, the pits formed by NRP2-depleted
osteoclasts were larger when compared to those from NRP2-positive
osteoclasts (Fig. 3a).
A striking difference was also observed in the expression of
osteoclastic markers. In comparison to the control osteoclasts, NRP2depleted osteoclasts expressed signiﬁcantly higher osteoclast
markers. RANK expression increased by 10-fold in NRP2-knockout
osteoclasts compared to NRP2-expressing cells. The expression of
TRAP, cathepsin K DC-STAMP, ATP6V0D2, carbonic anhydrase II (Car
II), ATP6i and matrix metalloprotease 9 (MMP9) increased in the
absence of NRP2 in osteoclasts (Fig. 3g, Supplementary Fig. 4j).
Like RANKL and M-CSF treatment, LNCaP C4-2B CM treatment led
to increased resorptive function of NRP2-deleted osteoclasts. NRP2
ablation increased pit absorption by nearly 45% by day 6 (Fig. 3b, e).
Further, osteoclasts in LNCaP C4-2B CM expressed exponentially
higher levels of osteoclast-associated genes following NRP2 deletion

compared to the control (Fig. 3h, Supplementary Fig. 4k). However,
resorption function of the NRP2-downregulated osteoclasts in PC3
CM did not differ from their control counterparts (Fig. 3c, f).
Furthermore, deletion of NRP2 caused either no change or a
decrease in the expression of osteoclastic genes in osteoclasts in PC3
CM (Fig. 3i, Supplementary Fig. 4l). Together, the data suggested that
NRP2 blockade increases osteoclastogenesis in osteoclasts induced
by osteosclerotic LNCaP C4-2B CM, but not in osteoclasts induced by
osteolytic PC3 CM.
NRP2 regulates downstream signaling in osteoclasts under
different differentiation stimuli
NRP2 regulates the expression and function of NFATC1 in osteoclasts
treated with RANKL and M-CSF, and LNCaP C4-2B CM but not PC3
CM. Our results indicated that NRP2 regulates the expression of
osteoclastic genes in osteoclasts treated with RANKL and M-CSF
as well as LNCaP C4-2B CM. We therefore evaluated whether
NRP2 controls NFATc1, a key transcription factor in osteoclastogenesis, under these conditions.28 Immunoﬂuorescence
Bone Research (2021)9:24
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Fig. 3 Depletion of NRP2 escalates the resorptive function and gene expression in osteoclasts. Knockout of NRP2 in osteoclastic precursors
isolated from NRP2 Fl/Fl; CSF1R-Cre transgenic mice by addition of 4-HydroxyTamoxifen in vitro and differentiated into osteoclasts in the
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studies showed that NFATc1 localization in the nucleus (a
measure of its activity) was higher in NRP2-null osteoclasts than
in NRP2-expressing osteoclasts during early differentiation in
day 2 and day 3 following RANKL and M-CSF, and LNCaP C4-2B
CM treatments (Fig. 4a, b, e, f Supplementary Fig. 5a–c, e).
NFATc1 expression continued to increase (Fig. 4e). The control
cells showed no or less localization of NFATc1 in the nucleus,
suggesting NFATc1 is mainly in the cytoplasm of osteoclasts
treated with LNCaP C4-2B CM (Fig. 4e). Since NFATc1 functions
as its own transcription factor and thus increases its own
expression, we analyzed the total level of NFATc1 in osteoclasts
following NRP2 knockout. Osteoclasts with NRP2 knockout
treated with either RANKL and M-CSF or LNCaP C4-2B CM
expressed higher levels of NFATc1 than osteoclasts with NRP2
(Fig. 4c, g, Supplementary Fig. 5d). Our results therefore
suggested that NRP2 negatively regulates NFATc1 in differentiating osteoclasts stimulated with LNCaP C4-2B CM or by RANKL
and M-CSF (Fig. 4k).
Bone Research (2021)9:24

In contrast to these ﬁndings, CM from the osteolytic PCa cells,
PC3, induced low or no activation of NFATc1 in osteoclasts even
after deletion of NRP2. NFATc1 localized in the cytoplasm but
not the nucleus in both NRP-2 expressing as well as depleted
osteoclasts in PC3 CM, as seen by immunoﬂuorescence staining
(Supplementary Fig. 6a, b). We also found very low or no
expression of total NFATc1 in the PC3 CM-treated osteoclasts,
and no change in the total protein was observed after depletion
of NRP2 (data not shown). This suggests that NRP2 does not
regulate NFATc1 in PC3 CM-induced osteoclasts.
NRP2 regulates intracellular calcium (Ca2+) levels upstream of
NFATC1 in osteoclasts. The activation of NFATc1 involves the
upstream function of the Ca2+/calmodulin pathway. Transient
increases in the levels of intracellular Ca2+ activate calmodulin,
leading to activation of its effector proteins, the calcium/
calmodulin-activated kinases (CaMKs) and calcineurin. The active
calcineurin dephosphorylates NFATc1 in a Ca2+-dependent
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addition of 4-HydroxyTamoxifen in vitro and differentiated into osteoclasts under different conditions. Confocal images showing NFATc1
translocation into the nucleus compared between NRP2WT and NRP2KO osteoclasts at day 3 of osteoclastic differentiation in a RANKL and
M-CSF, e LNCaP C4-2B CM. Insert represents the total ﬁeld from which the magniﬁed image was taken. b, f Quantiﬁcation of the mean
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Ca2+ release in d RANKL and M-CSF, h LNCaP C4-2B CM. Western blot analysis of NF-κB translocation status in nuclear and post nuclear
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translocation into the nucleus while only NFATc1 nuclear translocation is blocked by NRP2 in LNCaP C4-2B CM via the regulation of Ca2+
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manner to promote its translocation from the cytoplasm to the
nucleus for transcription of osteoclastic genes.29 To understand
how NFATc1 is activated in osteoclasts in the absence of NRP2,
we monitored the levels of intracellular Ca2+ using Fluo-4 in
osteoclasts in the presence and absence of NRP2. For this, we
used calcium indicator, Fluo-4, which binds to intracellular Ca2+
and monitor the changes in the levels of intracellular Ca2+. In
RANKL and M-CSF-treated osteoclasts, NRP2 depletion led to a 3fold increase in intracellular Ca2+ levels compared to NRP2expressing osteoclasts (Fig. 4d). Interestingly, intracellular Ca2+
levels were low in LNCaP C4-2B CM-treated osteoclasts until
removal of NRP2, which caused a fourfold increase (Fig. 4h).

In osteoclasts, binding of inositol-1, 4, 5-trisphosphate (IP3) to its
receptor IP3R can release Ca2+ from the endoplasmic reticulum
stores.30 To address whether IP3/ IP3R signaling causes this burst
of intracellular Ca2+ from the ER, we incubated osteoclasts with
2-APB, an allosteric inhibitor of IP3-induced Ca2+ release.31
Treatment with 2-APB decreased intracellular Ca2+ levels in
osteoclasts treated with RANKL and M-CSF (Fig. 4d). This
decrease was more profound in NRP2-knockout osteoclasts.
Treatment with 2-APB did not change the intracellular levels of
Ca2+ in LNCaP C4-2B CM treated-osteoclasts, but a signiﬁcant
decrease in Ca2+ levels was observed in NRP2-depleted
osteoclasts (Fig. 4h). These data together imply that increased
Bone Research (2021)9:24
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intracellular Ca2+ levels mediate the hyper activation of NFATc1
in the absence of NRP2 in osteoblasts stimulated with RANKL
and M-CSF as well as LNCaP C4-2B CM. Further, this increase in
intracellular Ca2+ is due to the activation of IP3/IP3R signaling,
which causes the calcium channels to release Ca2+ from the
ER reserves.

RANKL and M-CSF stimulation (Fig. 4i). These data were conﬁrmed
by immunoﬂuorescence staining of NF-κB (Supplementary Fig. 7a,
b). In summary, RANKL/M-CSF-treated osteoclasts express NRP2,
which controls the expression and localization of NFATc1 and
NF-κB during osteoclastic gene transcription. The absence of NRP2
in osteoclasts leads to their hyperactivation because of increased
activity of NFATc1 and NF-κB. Next, we evaluated the status of NFκB after depletion of NRP2 in osteoclasts treated with LNCaP C4-2B
CM. NRP2-expressing osteoclasts expressed NF-κB in the nucleus;
however, removal of NRP2 decreased these levels (Fig. 4j). This
data contradicts our ﬁndings in RANKL and M-CSF-induced
osteoclasts, suggesting that the increase in osteoclastic activity
following NRP2 depletion in osteoclasts differentiated by LNCaP
C4-2B CM is not dependent on NF-κB, but rather works centrally
through NFATc1. In the presence of PC3 CM, no change in NF-κB
was observed between control and NRP2-ablated osteoclasts.
NF-κB was localized in the cytosolic compartment but completely
absent in the nucleus in NRP2-expressing and -knockout

Osteoclastic NF-κB is not controlled by NRP2 in bone metastatic
prostate cancer. The coordinated function of NFATc1 with other
factors such as NF-κB has been widely studied in osteoclastogenesis. Hence, we investigated whether NRP2 regulates osteoclast
function via NF-κB. For this, we depleted NRP2 in osteoclastic
precursors and analyzed NF-κB protein localization via fractionation of nuclear and post-nuclear proteins (membrane and
cytoplasmic proteins). Control and NRP2-depleted cells treated
with RANKL and M-CSF expressed high levels of NF-κB. NRP2depleted osteoclasts also exhibited increased nuclear expression of
NF-κB compared with controls, which was further increased with
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osteoclasts (Supplementary Fig. 6c). These data indicate that
NF-κB is rendered inactive in both NRP2-expressing or knockout
conditions in PC3 CM-treated osteoclasts.
Altogether, NFATc1 is central to osteoclastogenesis induced by
metastatic PCa cells, which exhibit mixed osteoblastic/osteolytic
lesions. NRP2 controls NFATc1 to control osteoclast differentiation
and function. However, PC3 CM-treated osteoclasts are not
dependent on either NFATc1 or NF-κB for osteoclastogenesis
and evade the regulation of NRP2.
Osteoclastogenesis induced by PC3 factors follows a unique
differentiation program that bypasses NRP2
Our observations in the TRAP staining of osteoclasts induced by
CM of PC3 cells suggest that these osteoclasts do not differentiate
into large multinucleated cells but are restricted to either 2 or 3
nucleated osteoclasts (Fig. 2e). Also, the pits formed by these
osteoclasts are small and high in number (Fig. 3c, f). This indicates
that CM induces osteoclast to an extent that they are active even
in 2–3 nucleated state with moderate expression of osteoclastic
genes sufﬁcient for the resorptive function.
PC3 CM induced-osteoclastogenesis is independent of RANKL. PC3
and LNCaP C4-2B cells secrete different factors to regulate the
functioning of osteoclasts. Hence, we evaluated the secreted
factors in the CM of PC3 and LNCaP C4-2B cells. M-CSF, which is
a determinant in the commitment of myeloid progenitors into
osteoclast and macrophage precursors, is also involved in
osteoclastic differentiation via the RANKL signaling.27 We
analyzed these molecules by ELISA and detected very low
levels of RANKL, nearly 1 pg·mL−1 and 2 pg·mL −1 in the CM of
PC3 and LNCaP C4-2B cells, respectively (Fig. 5a); M-CSF levels
were around 500 pg·mL−1 in LNCaP C4-2B CM and 600 pg·mL −1
in PC3 CM (Fig. 5b). The presence of M-CSF in the CM of PCa
cell lines indicates early commitment of myeloid progenitors
to osteoclastic precursors, as seen by TRAP staining where we
observed mononucleated TRAP-positive cells. In a metastatic
bone microenvironment, RANKL could be provided by other
cells such as osteoblasts. Hence, we tested the differentiation
and function of osteoclasts in PC3 CM supplemented with
RANKL at a concentration of 50 ng·mL −1 (a dose frequently
used by researchers to induce osteoclast differentiation). We
observed that even at day 6 of differentiation, the osteoclasts
looked similar with and without RANKL. Further, no change
was observed after depletion of NRP2 in these conditions
(Fig. 5d, g). This suggests that the RANKL/RANK pathway is not
central to the differentiation of osteoclasts in the presence of
PC3 CM.
GMCSF in the CM of PC3 cells promotes differentiation toward an
immature dendritic cell phenotype and thus uncouples the negative
regulation of NRP2. To evaluate the osteoclast-promoting factors
in the CM of PCa cell lines, we conducted a cytokine array of 36
different cytokines. Interestingly, LNCaP C4-2B CM contained only
a few cytokines, such as CXCL1, CXCL12, IL-8, MIF, and Serpin E1 in.
Of these, IL-8 and CXCL1, which are positive inducers of
osteoclasts, were present in high levels (Fig. 5e, f). On the contrary
in PC3 CM, we detected several known osteoclast-inducing factors
such as CCL12, CXCL1, CXCL10, CXCL12, G-CSF, GM-CSF, IL-1β,
IL-1F3, IL-6, IL-8, IL-18, MIF, and Serpin E1 (Fig. 5e, f).32–40
Interestingly, GM-CSF is a potent inhibitor of early osteoclastic
differentiation and fusion and is abundant in the PC3 CM
(Fig. 5e, f).41,42 An ELISA showed low levels of GM-CSF in LNCaP
C4-2B CM and a high concentration of 590 pg·mL−1 in PC3 CM
(Fig. 5c). To test whether high GM-CSF levels can inhibit
osteoclast differentiation and fusion, we treated osteoclasts
with GM-CSF (600 ng·mL−1) combined with RANKL and M-CSF.
On both days 2 and 3 of osteoclastic differentiation, GM-CSF
treatment decreased the number of TRAP-positive osteoclasts

and delayed their fusion (indicated by an increased number of
mononuclear cells). Moreover, NRP2 deletion had no additional
effect on the differentiation and fusion of these osteoclasts
(Fig. 6a–d). Similar to RANKL and M-CSF treatment, GM-CSF
addition to LNCaP C4-2B CM signiﬁcantly reduced early
differentiation of NRP2-deleted osteoclasts. Speciﬁcally, at day
2 and day 3, GM-CSF treatment decreased the total number of
TRAP-positive mononuclear osteoclasts and delayed fusion of
the osteoclasts following NRP2 deletion (Fig. 6e–h). These results
suggest that GM-CSF is an inhibitor of early osteoclast
differentiation and fusion. The GM-CSF secreted by PC3 keeps
osteoclasts in a mononucleated state and thus helps the cells to
overcome the regulation of NRP2.
GM-CSF in high concentrations can induce immature dendritic
cell commitment, which can differentiate into TRAP-positive
osteoclasts via c-Fos.42 Therefore, PC3 CM-induced osteoclasts
can originate from immature dendritic cells rather than their
osteoclastic precursors, and this lineage switch contributes to
the evasion of NRP2 regulation in PC3 CM-treated osteoclasts. To
examine this, mononuclear cells were cultured in PC3 CM and
tested for the presence of dendritic markers. Our ﬂow cytometric
analysis revealed that these cells were CD11C positive (marker
for mature dendritic cells) with intermediate expression of
surface markers CD40 and CD86 and F4/80 (Fig. 6i). This result
suggests that PC3 CM drives mononuclear cells to become
immature dendritic cells, which then behave like osteoclasts.
NRP2 abrogation in osteoclasts prevents PCa to grow in bone
PCa bone metastasis is clinically characterized by high osteoblastic and moderate osteolytic lesions. We showed that
different PCa cells in bone can diversely activate osteoclasts
by modulating distinct molecular mechanisms. PCa cells like
LNCaP C4-2B, which predominantly form osteosclerotic lesions,
activate NRP2 in osteoclasts to inhibit their function; depletion
of NRP2 in LNCaP C4-2B CM-treated osteoclasts led to hyperosteolytic function, which could prove to be fatal if NRP2
inhibition was applied as a therapy for PCa bone metastasis.
Further, our cell culture system cannot recapitulate the complex
communication between different cells in the bone and PCa
cells, which promotes bone metastasis. To address these
questions, we utilized the same transgenic mouse model that
was used in the in vitro studies where NRP2 could be
conditionally deleted in the myeloid population (progenitors
of osteoclast) with the administration of tamoxifen (Fig. 7a).
Injection of RM1 cells (mouse PCa cell line syngenic to C57BL/6
background and promotes mixed bone lesions) into the tibia of
these transgenic mice signiﬁcantly increased tumor growth,
thereby causing severe bone loss in control mice (Fig. 7b, c).
Surprisingly in the mice where the myeloid cells were depleted
of NRP2, we observed decreased tumor burden in the tibia along
with increased bone rescue, which contradicts our initial
assumptions (Fig. 7b, c). Bone analysis showed severe bone
destruction in the control group compared with the NRP2deletion group, as conﬁrmed by parameters such as bone mass
density, bone volume/tissue volume, trabecular thickness and
number (Fig. 7d, g, h, i, j). Immunoﬂuorescence studies on the
bone tissues showed that the proliferation marker Ki67 was
lower in the tumor cells of the NRP2-knockout mice than in the
control mice (Fig. 7e, k). Additionally, cleaved caspase 3 staining
showed increased cell death in the NRP2-knockout mice
compared to the control group (Fig. 7f, l). The efﬁcacy of NRP2
knockout was conﬁrmed by protein analysis of the osteoclasts
isolated from the bone marrow of the mice from each group
(Fig. 7m). These data cumulatively demonstrate that NRP2
depletion in osteoclasts rescues the bone from the deleterious
effects of PCa cells by decreasing their proliferation and
increasing cell death. Altogether, our study indicates that
NRP2 is a promising target for treatment of PCa bone metastasis.
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Fig. 6 Addition of GM-CSF blocks the differentiation and fusion of osteoclasts. Knockout of NRP2 in osteoclastic precursors isolated from
NRP2 Fl/Fl; CSF1R-Cre transgenic mice by addition of 4-HydroxyTamoxifen in vitro and differentiated into osteoclasts in the presence of RANKL
and M-CSF, LNCaP C4-2B CM and PC3 CM. Under these conditions, one set as control and the other set treated with GM-CSF at 600 pg·mL−1.
TRAP staining to compare the osteoclast differentiation in NRP2WT and NRP2KO condition in RANKL+M-CSF at a Day 2. b Day 3. in LNCAP C42B CM e Day 2 f day 3. Quantiﬁcation and comparison of the number of TRAP-positive multinucleated osteoclast per well in NRP2WT and
NRP2KO osteoclasts with and without GM-CSF in RANKL and MCSF c Day 2 d Day 3 and in LNCaP C4-2B CM g Day 2 h Day 3. All values
reported as mean± SEM from two independent experiments. Statistically signiﬁcant P value denoted as *** (0.001), **** (0.000 1), ***** (0.000 001).
i Flow cytometric analysis of surface markers of mononucleated bone marrow cells differentiated by PC3 CM

DISCUSSION
The incidence of bone metastasis in advanced-stage PCa patients is
high (nearly 80%)43 and is one of the major reasons for patient
morbidity and mortality. Treatment strategies currently used for
bone metastasis are inadequate and palliative. Therefore, development of anti-metastatic agents that prevent the initiation and
progression of PCa bone metastasis is crucial. The results presented
here highlighted the potential of targeting the NRP2 axis as a novel
therapy for PCa bone metastasis. We observed homogeneously high
NRP2 expression in the majority of PCa bone metastasis specimens
compared to primary PCa. Importantly, depletion of NRP2 in PCa
cells when combined with chemotherapeutic stress caused tumor
cell death, leading to a signiﬁcant reduction of growth of metastatic
PCa in bone. This result thus validated our previous in vitro studies
where we observed that NRP2 deletion sensitized metastatic
Bone Research (2021)9:24

PCa cells to chemotherapeutic agents. Therefore, our data implicates
the NRP2 axis as a potential therapeutic target for PCa bone
metastasis and thus supports the future development of antibody,
peptide and small molecule-based inhibitors against NRP2 as
candidate drugs for bone metastatic PCa.
A systemic therapy targeting NRP2 in PCa bone metastasis is
unlikely to be speciﬁc for cancer cells and could potentially block
the NRP2 axis in other cells in the cancer microenvironment. Since
osteoclasts express NRP2 under normal physiological condition,20
we evaluated whether osteoclasts differentiated by the cytokines
and growth factors released by metastatic PCa cells also express
NRP2 and what would be the effect of inhibiting this expression.
We know that the metastatic PCa cells in bone induce osteoclasts,
which are predominantly dysfunctional.44,45 Unlike other cancers
such as breast and multiple myeloma where osteolytic lesions are
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Fig. 7 PCa-induced osteolysis is decreased by osteoclast-speciﬁc NRP2 depletion in vivo. a Schematic representation of the experimental
design of intratibial injection of RM1 cells into transgenic compound NRP2 Fl/Fl; CSF1R-Cre mice. The mice were divided into two groups:
control and test. The mice in control group received corn oil only and the test group was injected intraperitonially tamoxifen from day 3 of
intratibial inoculation of RM1 cells until the end of experiment. b Representative H&E images of tumor growth in control and NRP2KO groups.
c Tumor area calculated and represented as a graph with statistical signiﬁcance. d micro-CT images of trabecular compartment of the proximal
tibia showing bone changes in control and NRP2KO mice in comparison with the normal untreated bone. g–j Graphs showing bone mass
density (BMD), bone volume/tissue volume (BV/TV), trabecular thickness and trabecular number per mm area for each group. n = 6 mice were
used to analyze tumor bearing bones from three independent experiments. e, f Immunoﬂuorescence images depicting the status of Ki67 and
cleaved caspase 3 (pink) with respective tumor cells (red) in control and NRP2KO groups. k, l Graphical representation of the quantitation of
Ki67 and cleaved caspase 3 immunoﬂourescence (pink) normalized with area of tumor cells (red) and statistical signiﬁcance denoted as
P value * (0.05), ** (0.01), *** (0.001). m Western blot depicting the osteoclastic NRP2 expression in the control and NRP2KO mice used in the
experiment

predominant, the bone metastasis induced by PCa cells shows
mixed osteoblastic and osteolytic lesions, with greater abundance
of the former.1,10,12,46 Therefore, it would be difﬁcult to predict
how tumor growth in bone would be affected if a therapy
perturbs the function of osteoclasts and thereby disturbs the
crosstalk between tumor cells, osteoblasts and osteoclasts in the
tumor microenvironment. To address this, we studied the role of
NRP2 in PCa-induced osteoclasts and the effect of NRP2 inhibition
on tumor growth. Our study showed that upon differentiation by
PCa cells, osteoclasts express high NRP2 levels. Intriguingly, NRP2
depletion increased osteoclast differentiation and activation and
increased expression of osteoclastic genes in osteoclasts treated
with LNCaP C4-2B CM, which was similar to effects observed in

osteoclasts treated with RANKL and M-CSF (mimicking normal
physiological condition). NRP2-depleted osteoclasts formed
large, multinucleated polykaryons and exhibited higher resorbing
capacity than their control counterparts. Contrary to these
observations, osteoclasts stimulated by osteolytic PCa cells
such as PC3 did not show any change in differentiation and
activation upon depletion of NRP2. Collectively, we showed that
NRP2 negatively regulates the differentiation and function of
osteoclasts induced by LNCaP C4-2B cells, which in turn promotes
mixed lesions, as observed in the majority of PCa patients
with bone metastasis. Interestingly, PC3 cells, which promote
mainly osteolytic lesions, induce osteoclasts through an NRP2independent mechanism.
Bone Research (2021)9:24
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The ﬁnding that NRP2 regulates osteoclastic gene expression
directed our attention towards participating transcription factors.
Hence, we evaluated whether NRP2 regulates the function of
transcription factors NFATc1 and NF-κB, reported to be central to
osteoclast differentiation.29,47,48 Compelling evidence from protein
and immunoﬂuorescence analysis indicated that NRP2 inhibits the
expression and localization of NFATc1 when osteoclasts are
induced by osteosclerotic LNCaP C4-2B or treated with RANKL
and M-CSF. This suggests that NRP2 negatively regulates NFATc1,
a master regulator of osteoclastogenesis. NFATc1 expression is
regulated by its upstream signaling, which includes Ca2+
signaling.29,49,50 Our studies indicated that the osteoclasts devoid
of NRP2 released more intracellular Ca2+ from ER reserves,
promoted by the activation of IP3/IP3R signaling, compared with
NRP2-expressing osteoclasts. We therefore concluded that the
NRP2 axis regulates IP3/IP3R signaling in osteoclasts and thus
controls intracellular Ca2+ levels and downstream activation of
NFATc1. Interestingly, NRP2 also controls NFκB activation in
RANKL and M-CSF-treated osteoclasts. In the absence of NRP2,
NFκB works cooperatively with NFATC1 to induce osteoclastspeciﬁc genes and thus hyper-activate osteoclast function.
Currently, it is unknown why NF-κB is not activated in osteoclasts
induced by the CM of LNCaP C4-2B. However, this lack of NFκB
activation helps to explain why the expression levels of
osteoclastic genes were not comparable to the levels we observed
in RANKL/M-CSF-treated osteoclasts despite signiﬁcant translocation of NFATc1 in the nucleus of LNCaP C4-2B CM-treated
osteoclasts following NRP2 depletion.
Although NRP2 expression was observed in PC3 CM-induced
osteoclasts, NRP2 depletion did not change the differentiation and
function of osteoclasts. In our initial ﬁndings, we observed that PC3
CM-induced osteoclasts expressed signiﬁcant levels of osteoclastic
genes and were not inﬂuenced by the status of NRP2. This hints
that PC3 CM activates transcription factors that are not regulated by
NRP2 to enable the expression of osteoclastic genes. We did not
observe the localization of NFATc1 and NF-κB in the nucleus of PC3
CM-induced osteoclasts, suggesting that PC3 CM does not activate
these transcription factors. Further studies should clarify the
signaling pathways activated by PC3 CM. Also, PC3 CM induced
osteoclasts in a 2–3 nucleated state, with resorptive function limited
to pore formation rather than large pits. This raised the question of
what in the PC3 CM is restricting the fusion and function of
osteoclasts. Cytokine analysis of the PC3 CM showed high
concentration of GM-CSF, which is a reported inhibitor of early
differentiation and fusion in osteoclasts. Addition of GM-CSF caused
a delay in the early differentiation and fusion of osteoclasts treated
with RANKL and M-CSF, or LNCaP C4-2B CM. In addition, NRP2depleted osteoclasts treated with GM-CSF also showed a lag in their
differentiation and fusion. This phenomenon could be a result of
uncoupling between GM-CSF and NRP2 regulation pathways, and
further conﬁrms that GM-CSF in PC3 CM restrains osteoclast
differentiation and fusion. It will be important to study whether
removal of GM-CSF from the PC3 CM can restore regulation by
NRP2 in osteoclasts. In addition to these ﬁndings, our ﬂow
cytometric analysis of osteoclasts differentiated by PC3 CM showed
characteristics of immature dendritic cells that retained the ability
to differentiate into osteoclast-like cells. Furthermore, PC3 CM
promoted the differentiation of mononuclear cells into immature
dendritic cells, which when presented with osteoclastic growth
factors became osteoclast-like cells. Thus, osteoblasts stimulated by
PC3 CM evade NRP2 regulation, which is prominent in osteoclasts
generated by RANKL and M-CSF and LNCaP C4-2B CM.
Our in vitro studies suggest that targeting NRP2 for treatment of
bone metastasis could lead to different scenarios in PCa patients
with mixed lesions. Since PCa promotes predominantly osteoblastic bone formation, an approach that enhances osteolytic activity,
e.g. targeting NRP2, may interfere with prostate cancer growth in
bone. To address this critical question, we used a syngenic mouse
Bone Research (2021)9:24

tumor model of PCa bone metastasis, where NRP2 was speciﬁcally
deleted from osteoclasts. The results from these in vivo studies
revealed that depletion of NRP2 from osteoclasts signiﬁcantly
decreases tumor burden. Even with increased osteoclasts, the
bone showed less damage in the tumor-bearing NRP2-knockout
mice compared to their control counterparts mainly due to less
tumor growth and thus less tumor-induced osteolysis. This effect
could result from two scenarios: (1) Removal of NRP2 from
osteoclasts in the bone microenvironment increased osteolytic
function to a level that overcame the hyper osteoblastic activity,
thereby inhibiting the tumor niche in bone and inducing tumor
cell death. (2) Using cre recombinase under the control of CSF1R
can cause NRP2 knockout from not only osteoclasts but also cells
of myeloid lineage such as macrophages and dendritic cells. Our
previous work on macrophages showed that NRP2 controls their
phagocytic function and its depletion can impair the clearance of
apoptotic cells, leading to tumor suppression.51 Hence, the loss of
NRP2 from macrophages may have caused a ripple effect on tumor
growth inhibition in bone, which is beyond the scope of this study.
Since any systemic therapy targeting NRP2 would block its
function not only in osteoclasts but also in other myeloid cells,
we expect our syngeneic mouse model simulates use of an NRP2
inhibitor to treat PCa bone metastasis. In summary, our study
demonstrated that targeting NRP2 may prove to be effective in the
treatment of PCa bone metastasis.
MATERIALS AND METHODS
Reagents
RPMI 1640 medium, DPBS, 0.25% (w/v) trypsin, MEM Non-Essential
Amino Acid solution (100×), sodium pyruvate (100 mmol·L−1),
HEPES (1 mol·L−1) and Penicillin-Streptomycin (5 000 U·mL−1)
were procured from ThermoFisher Scientiﬁc. Minimum Essential
Medium (MEM) Alpha Medium (10-022-CV) was purchased from
Corning. Fetal bovine serum and goat serum were obtained
from GIBCO.
Antibodies such as NRP2 (D39A5), NF-κB (D14E12), α-actin
(D6D8), and histone H2A (D603A) were purchased from Cell
Signaling Technology, NFATc1 (7A6) from ThermoFisher Scientiﬁc,
HDAC1(ab7028) from Abcam, Rho-GDI (C2, sc-374579) and HSC70
(B-6, sc-7298) from Santa Cruz Biotechnology. Secondary antibodies were ordered, including goat anti-rabbit IgG-HRP (sc-2004)
from Santa Cruz Biotechnology and sheep anti-mouse IgG-HRP
(AC111P) from EMD Millipore. Secondary antibodies conjugated
with Alexa ﬂuor such donkey anti-rabbit Alexa Fluor 546 for NF-κB
(A10040) and goat anti-mouse Alexa Fluor 660 for NFATc1
(A21054) were obtained from ThermoFisher Scientiﬁc. siRNAs
against mouse NRP2 and non-targeting control (ON-TARGET plus,
smart pool) were purchased from Dharmacon. Recombinant
murine M-CSF (315-02) and RANK ligand (315-11) were acquired
from Peprotech. TRAP staining kit was purchased from Cosmo Bio
(PMC-AK04F-COS) and osteo assay surface microplates (24-well,
#3987) from Corning. Reagents such as (Z)-4-Hydroxytamoxifen
(H7904), HEPES, KCl, DTT, NP-40, glycerol, MgCl2, EDTA, PMSF,
cyclosporine A, and protease inhibitors such as aprotinin and
leupeptin were purchased from Sigma-Aldrich. Halt, Trizol and
Powerup SYBR Green master mix were bought from ThermoFisher
Scientiﬁc. The cDNA kit was obtained from Roche and primers
from IDT. Fluorochrome-conjugated antibodies anti-mouse BV510
CD11c (117337), APC CD40 (124611) and PE/Cy7 CD86 (105013)
were purchased from Biolegend (San Diego, CA) and anti-mouse
PE F4/80 (12-4801-82) from eBioscience (San Diego, CA) for FACS.
Flou-4 (F14201) was obtained from ThermoFisher Scientiﬁc.
Mouse models
All mice used in this study were maintained under speciﬁc
pathogen-free conditions. All procedures performed were in
accordance with institutional guidelines and approved by the
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University of Nebraska Medical Center Institutional Animal Care
and Use Committee (IACUC). Our study used two different mouse
models, C57BL/6 and transgenic CSF1R-cre; NRP2ﬂoxed/ﬂoxed mice.
The C57BL/6 mice were purchased from Charles River at the age of
6–10 weeks for isolation of bone marrow.
Generation of transgenic CSF1R-cre; NRP2 Flox/Flox mice: The
NRP2ﬂoxed/ﬂoxed mouse was developed in Max Planck Research
Unit for Neurogenetics by Dr. Peter Mombaerts. Our research
collaborator in University Hospital Bonn, Germany, Dr. Michael
Muders gave them as a kind gift to us. The transgenic FVB-Tg
(Csf1r-Mer-iCre-Mer)1Jwp/J mice were purchased from Jackson
Laboratories. These mice express a Cre recombinase/mutant
murine estrogen receptor double-fusion protein under the control
of the Csf1r (colony-stimulating factor 1 receptor) promoter. The
Tg(Csf1r-Mer-iCre-Mer)1Jwp mice were bred with NRP2ﬂox/ﬂox mice
to obtain CSF1R-Cre; NRP2ﬂoxed/ﬂoxed mice which express a
tamoxifen-inducible Mer-iCre fusion protein driven by the Csf1r
promoter, which upon administration with either tamoxifen
intraperitoneally (75 mg·kg−1 body weight) in mice or (Z)-4Hydroxytamoxifen in vitro leads to activation of Cre recombinase.
The Cre recombinase targets the deletion of NRP2 in the loxPﬂanked regions. The ablation of NRP2 occurs in myeloid cells as
they speciﬁcally express CSF1R.
Retrospective study of human PCa bone metastasis
A commercially available PCa bone metastases array was
purchased from Tristar in 2010 (Tristar TMA number 79562475).
The core diameter of each sample was 0.6 mm. The tissue
microarray contained samples of ﬁfty PCa bone metastases, ﬁve
normal bones as a control, and ﬁve primary PCa as a control. A
control group of primary PCa was obtained through the
Biospecimen Accessioning and Processing (BAP) and Tissue and
Cell Molecular Analysis (TACMA) Shared Resources at Mayo Clinic.
All patients were treated between 1992 and 1997 by radical
prostatectomy at Mayo Clinic under the IRB protocol. The cohort
contained three groups of patients (total 130 patients). All patients
had locally advanced PCa without any locoregional or distant
lymph node or bone metastases (pathological stages pT3aN0
and pT3b/pT4N0). 50 patients received no adjuvant therapy,
50 patients received adjuvant hormonal therapy, and 30 patients
received radiation therapy. Two board-certiﬁed pathologists
scored the primary tumor and the bone metastases TMA (Raffael
Jimenez and Michael Muders).
For the immunohistological staining, tissues were deparafﬁnized and rehydrated followed by antigen unmasking and
blocking. NRP2 antibody from Santa Cruz was used (clone c9,
dilution 1:150) and the cell pellet of PC3 was used as a control. As
a negative control, PC3 with siRNA-mediated NRP2 depletion was
used. Mouse IgG antibodies were used as an isotype control
(Supplementary Fig. 1e). The Dako Envision Plus Detection Kit was
used to detect staining. In the evaluation of staining, interobserver
variability (Cohen’s kappa co-efﬁcient) was tested. Based on the
distribution, staining intensity or area was dichotomized ranging
from none or weak, moderate to strong intensity. The differences
in the staining of the primary PCa and bone metastasis was
summarized using a frequency table. All tests were two-sided with
P values less than or equal to 0.05 considered signiﬁcant.
PCa cell lines
PC3 and LNCaP C4-2B cells were cultured in RPMI complete
medium supplemented with 10% fetal bovine serum (FBS) and
antibiotics (Penicillin-streptomycin). RM1 cells were cultured in
DMEM complete medium. Upon conﬂuency, these cells were
washed with DPBS and either brieﬂy rinsed (LNCaP C4-2B) or
treated with 0.25% (w/v) trypsin-EDTA (PC3 and RM1) to detach
cells from the plate. The cells were collected in equal volumes of
complete medium to neutralize the effect of trypsin. The cells
were pelleted by centrifugation at 1 000 × g for 5 min. The cells

were then suspended in fresh complete media, plated in a T-175
ﬂask, and cultured in a tissue culture incubator maintained at 37 °C
and 5% CO2.
Collection of conditioned medium
To collect conditioned medium (CM) from PC3, LNCaP C4-2B and
RM1, 1 × 106 cells were plated in a T-75 culture ﬂask and allowed
to grow until 70% conﬂuency. Cells were then washed with DPBS
and incubated with 5 mL of fresh serum-free RPMI complete
medium. The cells were then incubated for another 24 h to collect
the CM. The CM was then centrifuged at 1 000 × g for 5 min to
remove cells and cell debris and ﬁltered using a 0.45 m ﬁlter to
remove any residual debris. The CM was either used fresh for
experiments or aliquoted in small volumes based on usage and
stored at −80 °C for future use.
Isolation of mouse bone marrow-derived osteoclasts
Mouse osteoclastic precursors were isolated from 6 to 10-weekold C57BL/6 male mice and transgenic mice (CSF1R-Cre; NRP2ﬂox/
ﬂox) after euthanizing by cervical dislocation. Long bones from
the mice were harvested, and the bone marrow was collected by
ﬂushing the bones with DPBS. The bone marrow was subjected to
centrifugation at 2 000 × g for ten min, and the pellet obtained was
suspended in MEM alpha medium containing 10% FBS, 1%
antibiotic, 1% sodium pyruvate, and 1% MEM Non-Essential Amino
Acid and HEPES (pH 7.4). The cells were then ﬁltered through a cell
strainer to remove ﬁbrous cellular debris and make a single cell
suspension. The cell suspension was then centrifuged, and the
pellet was subjected to a Ficoll-Paque gradient to isolate mononuclear cells. These cells were plated in MEM alpha complete
medium containing 10 ng·mL−1 of recombinant murine M-CSF and
cultured overnight to separate macrophages (which will attach to
the surface of the plate); the non-adherent cells were harvested to
be used as osteoclastic precursors for all the experiments.
Three different culturing conditions were applied to mimic
physiological and pathological bone metastasis. Osteoclastic
precursors were differentiated into healthy osteoclasts by addition
of 20 ng·mL−1 of recombinant M-CSF and 100 ng·mL−1 of
recombinant RANK ligand, or CM from PC3, LNCaP C4-2B and
RM1 cells (20% v/v) were mixed with MEM alpha complete
medium for seven days with a boost of growth factors every
alternate day from the start of the experiment. Every consecutive
day, cells were supplemented with RANKL and M-CSF or CM. On
day 7, the mature osteoclasts from all the three conditions were
then used for isolation of protein or RNA based on the experiment
conducted.
Depletion of NRP2 using RNA interference and knockout model
NRP2 was depleted in osteoclastic precursors isolated from C57BL/6
mice using the Lonza nucleofector kit (VPA-1007) and nucleofector
2b device. The procedure followed for nucleofection was as per the
manufacturer’s protocol. 25 nmol·L−1 of NRP2 and scrambled siRNA
were used. After nucleofection, the osteoclast precursors were
maintained in nucleofector solution containing medium for 8 h and
then incubated with MEM alpha complete medium containing
either M-CSF and RANK ligand or CM from prostate cancer cell lines
and allowed to differentiate for seven days.
Osteoclastic precursors isolated from transgenic mice CSF1R-Cre;
NRP2ﬂox/ﬂox were treated with 0.3 μmol·mL−1 of (Z)-4-Hydroxytamoxifen to deplete NRP2 from osteoclasts speciﬁcally. A parallel set
of osteoclastic precursors where no (Z)-4-Hydroxytamoxifen was
added served as the control for each experiment. The control and
knockout osteoclastic precursors were then differentiated into
mature osteoclasts (7 days) under different conditions.
Tartarate-resistant acid phosphatase staining
To conﬁrm the presence of osteoclasts, TRAP staining was
conducted. Cells were washed with PBS and ﬁxed with 10%
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NRP2 in prostate cancer bone metastases
NS Polavaram et al.

13
formalin at room temperature for 10 min. The osteoclasts were
washed with deionized water, and 150 μL of the chromogenic
substrate was added and incubated at 37 °C for 1–2 h. Cells were
then washed with deionized water and 2 or more nucleated TRAPpositive cells were counted and represented graphically.
Pit formation assay
Mouse osteoclastic precursors were plated in each well of the
osteoassay plate under different conditions to analyze the efﬁcacy of
the treatment conditions. To visualize the pits, 10% bleach diluted in
deionized water was added for 10 min at room temperature and
washed with deionized water and dried for 3 to 5 h at room
temperature. Pit clusters were observed and captured using phase
contrast microscope. Images obtained were analyzed for the
measurement of coated surface resorbed using ImageJ and
normalized with total surface area of the well of a 24-well osteoassay
plate. The percent surface area resorbed was calculated and plotted
with standard error under different treatment conditions.
Immunobloting
For protein analysis, osteoclasts were washed with PBS to remove
any traces of media. The cells were lysed with ice cold lysis buffer
containing CHAPS buffer pH 7.4 (40 mmol·L−1 HEPES, 0.3% CHAPS,
10 mmol·L−1 Glycerophosphate, mmol·L−1 sodium pyrophosphate, 2 mmol·L−1 EDTA) and combination of protease inhibitors,
20 µg·mL−1 Leupeptin, 10 µg·mL−1 Aprotinin, 1 mmol·L−1 PMSF
and Halt protease.
For separation of nuclear and post-nuclear fraction in osteoclasts, 250 µL of buffer A (10 mmol·L−1 HEPES pH 7.8, 10 mmol·L−1
KCl, 2 mmol·L−1 MgCl2, 0.1 mmol·L−1 EDTA, 10 µg·mL−1 Leupeptin,
10 µg·mL−1 Aprotinin, 3 mmol·L−1 DTT, 1 mmol·L−1 PMSF and Halt
protease) was added to each sample and incubated on ice for
17 min. 20 µL of 10% NP- 40 detergent was added to each sample
containing buffer A and vortexed for 2 min and centrifuged at
14 000 r·min−1 for 5 min. The supernatant containing the postnuclear proteins was separated from the pellet and labeled for
protein analysis. The pellet was resuspended in 50 µL of buffer C
(50 mmol·L−1 HEPES pH 7.8, 50 mmol·L−1 KCl, 300 mmol·L−1 NaCl,
0.1 mmol·L−1 EDTA, 10% (v/v) glycerol, 10 µg·mL−1 Leupeptin,
10 µg·mL−1 Aprotinin, 3 mmol·L−1 DTT, 1 mmol·L−1 PMSF and Halt
protease) and vortexed and placed on a rotating rack for 1 h to
dissolve the pellet containing the nuclear proteins. The dissolved
pellet was then centrifuged at 14 000 r·min−1 for 10 min. The
supernatant containing the nuclear proteins was separated from
the pellet which contains DNA.
Total protein was estimated using Bradford reagent and the
samples were prepared by the addition of SDS sample buffer
containing β-mercaptoethanol and boiled at 95 °C for 5 min. The
prepared samples were run on a precast 4%–20% Mini-PROTEAN®
TGX™ Gel (BioRad) and transferred on to a PVDF membrane (Life
Technologies). The membrane was blocked in 5% non-fat dry milk in
1X TBST (1X Tris Buffered Saline, 0.1% Tween-20) for at least 30 min
and primary antibody diluted in 1X PBS was added and incubated
overnight at 4 °C with continuous shaking at low speed. On the next
day, membrane was washed with 1X TBST for four times for 5 min
and incubated in appropriate dilution of secondary antibody
conjugated with HRP for 1 h in 1X TBST with continuous shaking
at low speed at room temperature. Following this, the membranes
were washed in 1X TBST every 5 min for at least 5–7 times, and the
protein bands were detected using a combination dilution of
SuperSignal™ West Femto Maximum Sensitivity Substrate and
SuperSignal™ Pico Maximum Sensitivity Substrate captured on an
X-ray ﬁlm. the protein bands were identiﬁed and compared and
presented as an image using ImageJ software.
Real-time quantitative PCR
On day 7, osteoclasts were washed twice with PBS. Total RNA was
isolated by adding 1 mL of TRIzol Reagent (ThermoFisher
Bone Research (2021)9:24

Scientiﬁc, CA) per 1 million cells as per manufacturer’s protocol
and allowed to stand for 5 min at room temperature. Phase
separation by chloroform followed by RNA precipitation with
ethanol was done. The supernatant obtained by centrifugation
was decanted, and the pellet was air-dried brieﬂy resuspended in
DEPC-treated water. The concentration and quality of the RNA
were analyzed using Nanodrop Spectrophotometer.
cDNA was synthesized with Transcriptor First strand cDNA
synthesis kit (Roche Diagnostics Corporation) as per the instructions
provided by the manufacturers. 1 g RNA was used to generate cDNA.
For real-time PCR, cDNA (50 ng) was used, and each reaction was
performed in duplicates in 25 μL volume in a 96-well PCR plates
using SYBR green detection system (Applied Biosystems Group) in
an ABI 7500 Fast and Real-Time PCR (2 min at 50 °C, 10 min at
95 °C and 40 cycles of 15 s at 94 °C and 1 min at 60 °C) with
200–300 nmol·L−1 concentration of primers. The list of the primers
used in this study is listed in table (Supplementary Table 1). The
expression was calculated relative to that of control cells and
normalized with 36B4 measured under the same conditions (Applied
Biosystems/Roche, Branchburg, NJ), using the 2–ΔΔCT method.
Enzyme-linked immunosorbent assay (ELISA)
Human M-CSF and GM-CSF Quantikine ELISA kits were procured
from R&D systems (cat.no. - DMC00B, DGM00, respectively) and
Human RANKL from Abcam (cat.no. - ab213841) to measure the
amount of these cytokines in the conditioned media obtained
from PC3 and LNCaP C4-2B cell lines. The assays were conducted
according to the standard protocol provided by the manufacturer.
For wavelength correction, readings were obtained at 540 nm or
570 nm, and these reading were subtracted from readings at
450 to correct optical imperfections of the plate.
Cytokine proﬁling assay
To detect the expression levels of cytokines and chemokines in
the conditioned media, proteome proﬁler array (human cytokine
array panel A, cat.no. ARY005) from Abcam was used. According to
the array procedure, the nitrocellulose membrane containing 36
different capture antibodies was blocked with blocking buffer. The
blocking buffer was removed from the membranes and the
solution containing the conditioned media and the antibody
cocktail was added and incubated on a rocking platform shaker
overnight at 4 °C. On the following day, the membranes were
washed with washed buffer thrice and 2 mL of the solution
containing streptavidin-HRP was added to the membranes and
incubated at room temperature for 30 min on a rocking platform
shaker. The membranes were washed and chemiluminescent
detection reagent mix was added sequentially developed using an
x-ray ﬁlm developer. The cytokines were identiﬁed by aligning the
transparency overlay template on the array image and pixel
density was measured using imageJ software and represented as
a graph with statistical signiﬁcance.
In vivo mouse model of prostate cancer bone metastasis
All animal studies were conducted in accordance with the
University of Nebraska medical center IACUC guidelines. To
evaluate the role of NRP2 in PCa growing in bone and its
potential in combination with chemotherapy, intratibial injections
of LNCaP C4-2B were conducted in NOD SCID male mice in the
age group of 8–12 weeks purchased from Jackson labs. 100 000
cells per 20 µL of LNCaP C4-2B expressing GFP- luciferase and
inducible NRP2 shRNA under the control of doxycycline
suspended in PBS were injected into the left tibia of mice. The
right tibia received PBS only. Tumor burden in the bone was
monitored by IVIS imaging and after 7 days of injection, the mice
were randomized into four groups with 10 mice in each group.
The ﬁrst group acts as a control and received sucrose in water.
The second group received doxycycline in water (2 mg·mL−1;
5 mg·kg−1 body weight) to deplete NRP2 in the cancer cells.
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The third group was injected intraperitoneally with docetaxel
(5 mg·kg−1 body weight: once every 7 days for 3 weeks) and
sucrose in water. The fourth group received docetaxel injection
and doxycycline in water. After 3 weeks, all mice were sacriﬁced
and the tumor cells containing bones were obtained. Bone
marrow from three bones from each group were used to sort
tumor cells expressing GFP by ﬂow cytometry. These tumors cells
were processed to obtain RNA and Real-time PCR was conducted
to check the efﬁciency of NRP2 depletion. The rest of tumor
bearing bones were formalin-ﬁxed for further processing and
evaluation.
Intratibial injection of RM1 expressing RFP were conducted
in 8-12-week male transgenic mice (CSF1R-Cre; NRP2ﬂoxed/ﬂoxed)
to understand the effect of NRP2 depletion in osteoclasts on
the tumor growth in bone. 50 000 RM1 cells were injected into
the tibia of mice and allowed to grow for four days. Since RM1
is highly osteolytic, the time frame for the tumor growth is less.
On fourth day, the mice were randomized into two groupscontrol and test. The control group received corn oil injection
and the test group received Tamoxifen (75 mg·kg−1 body
weight from a 20 mg·mL−1 stock prepared in corn oil)
intraperitonially (i.p.). After 14 days, the mice were euthanized
and the bones with tumor cells was excised and formalin-ﬁxed
for further processing. Bone marrow from the non-tumor
bearing leg was collected and processed to culture osteoclasts
to check the efﬁciency of NRP2 depletion after administration
of tamoxifen.
Bone assessment
For micro-CT analysis, formalin-ﬁxed bones were scanned using a
high-resolution X-ray microtomography system (Skyscan 1172,
Bruker, Kontich, Belgium). The X-ray source was set as follows:
55 kV and 181 μA, resolution 8.89 µm, exposure time 815 ms, and
aluminum ﬁlter 0.5 mm-thick. To generate 3D images, scanning
raw data were reconstructed using NRecon software. The position
of each bone was corrected and saved with DataViewer. For bone
quality analysis, a consistent region of interest (ROI) around tibial
growth plate was identiﬁed. The ROI starts at the 50th slide above
the medial tibial plateau and continues downward through tibia
growth plate for 200 slides totally. The bone histomorphometric
parameters, including mean bone volume (BV), bone volume/
tissue volume (BV/TV), trabecular thickness (Tb.Th) and bone
mineral density (BMD) were determined using CT-Analyzer software. For histomorphometry, bones were parafﬁn embedded,
sectioned and stained for H&E. Tumor area was calculated using
ventana image viewer and plotted as a bar graph.
Immunoﬂuorescence
Osteoclasts were grown in glass chamber slides for better
attachment and convenience of staining. Osteoclasts were
washed with 1X PBS three times and ﬁxed with 4% buffered
formaldehyde for 15 min. Following ﬁxation, the cells were
washed with 1X PBS and blocked with 0.3% TritonX-100 and 5%
goat serum in 1X PBS for 1 h. The primary antibody (1:500 dilution)
prepared in the blocking buffer was added to the cells and
incubated overnight at 4 °C. On the next day, the cells washed
with 1X PBS containing 0.3% TritonX-100 and incubated in the
secondary antibody (Alexa-546 for NF-κB and Alexa-660 for
NFATc1) diluted 1:1 000 in 0.3% TritonX-100 and 5% goat serum
in 1X PBS for 1 h at 4 °C in the dark. After completion of secondary
antibody incubation, the cells were washed and mounted with
mounting solution containing DAPI and covered with a glass
coverslip and sealed.
For bone tissues, parafﬁn-embedded tissues were deparafﬁnized and rehydrated with xylene followed by a series of ethanol
washes. Antigen epitopes were revealed by boiling the tissues in
1X citrate based (pH 6.0) antigen unmasking solution (Vector
laboratories) for 15 min and allowed the tissues to cool down to

room temperature. The tissues were washed twice with distilled
water and treated with 3% hydrogen peroxide in methanol for
20 min. Following this, the tissues were washed with distilled
water and incubated in blocking buffer (5% goat serum in Trisbuffered base containing tween 20) for 1 h at room temperature.
The tissues were incubated in primary antibody (1:500 dilution of
Ki 67 (D3B5) and cleaved caspase 3 (Asp 175) from cell signaling)
diluted in blocking buffer overnight at 4 °C. After washing with
1X PBS thrice, secondary antibody tagged with ﬂuorochrome
was applied for 1 h. The tissues were washed in 1X PBS and
mounted with mounting media containing DAPI and sealed. The
cells and tissues were observed using Zeiss LSM 800 with
Airyscan microscope located in the UNMC confocal core facility,
and data were acquired, analyzed, and processed with the Zeiss
Zen 2010 software. All confocal data quantiﬁed using ImageJ
software and graphical illustrations made using GraphPad Prism
software.
Intracellular Ca2+ Imaging
Bone marrow-derived mononuclear cells were plated on 35 mm
poly-L-lysine-coated glass bottom ﬂuorodishes (differentiated into
osteoclasts in either M-CSF and RANKL or LNCaP C4-2B CM. At day
3, osteoclasts were loaded with 5 µmol·L−1 Flou-4 AM for 30 min at
RT in loading solution: 115 mmol·L−1 NaCl, 5.4 mmol·L−1 KCl,
1 mmol·L−1 MgCl2, 20 mmol·L−1 Hepes, and 10 mmol·L−1 glucose,
pH 7.4. The cells were washed with PBS thrice and loading solution
with 1% FBS was added to the cells. Live cell imaging was
conducted with Zeiss LSM 710 with Airyscan microscope and the
ﬂuorescent intensity was recorded simultaneously during the time
series. Intracellular Ca2+ levels with Flou-4 AM were analyzed
using excitation wavelength at 494 and an emission wavelength
at 506 nm. The corrected ﬂuorescent intensities of control and
NRP2-depleted osteoclasts were calculated and represented at a
graph. To inhibit the release of intracellular Ca2+ from the ER,
2-aminoethoxydiphenyl borate (2-APB, 50 µmol·L−1) was added to
the cells for 30 min prior to loading Fluo-4 AM.
Flow cytometry
Murine osteoclastic precursors were treated with PC3 CM for 24 h
and then analyzed by FACS for the presence of immature dendritic
markers. Brieﬂy, after 24 h of incubation with PC3 CM, the cells
were washed with PBS and incubated with ﬂuorochromeconjugated antibodies (BV510 CD11c, APC CD40, PE/Cy7 CD86
and PE F4/80) in FACS buffer (25 mmol·L−1 HEPES, 1% FBS,
1 mmol·L−1 EDTA in HBSS) for 30 min in dark at 4 °C. The cells were
washed with PBS twice to remove unbound antibody and
resuspended in FACS buffer and passed through a cell strainer
and collected in FACS tubes for analysis. Data was acquired using
BD LSR II with BD FACSDiva software (BD Bioscience, CA).
Compensation was performed on the BD LSR II ﬂow cytometry
at the start of the experiment and data analysis was conducted on
FlowJo v10 and represented as graphs.
Statistical signiﬁcance
Data are presented as mean ± standard error of the mean (SEM).
Statistical analysis was performed using the standard two-tailed
Student’s t-test using PRISM-6 software (GraphPad Inc.). Statistical
comparisons of more than two groups were performed using
unpaired student t-test. In all cases, a P < 0.05 was considered as
highly signiﬁcant.
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